BIT:RECPharmaceuticals
The Bull Case For Recordati (BIT:REC) Could Change Following Strong H1 Earnings And Reaffirmed 2026 Guidance
Recordati Industria Chimica e Farmaceutica S.p.A. recently reported past half-year 2026 results, with sales of €1,410.78 million and net income of €269.67 million, and confirmed its full-year 2026 net revenue guidance range of €2.73 billion to €2.80 billion.
The combination of higher sales, stronger earnings per share from continuing operations, and maintained revenue guidance highlights management’s confidence in operational performance and visibility on demand.
We’ll now examine how...